Erectile dysfunction is recognized as a quality-of-life disorder that needs to be treated. Currently, it is estimated to affect as many as 30 million American men. Thirty percent of hypertensive patients complain of erectile dysfunction. The understanding of common mechanisms involved in the cause of erectile dysfunction associated with hypertension, and the investigation of antihypertensive drugs that impact erectile dysfunction, will provide important tools toward identifying new therapeutic targets that will improve the quality of life for patients in these conditions.
INTRODUCTION
Erectile dysfunction is a condition of increasing prevalence worldwide, which has been estimated to affect 150 million individuals and is supposed to impact up to 50% of men between the ages of 40-70 years [1] . Also, it is expected that 322 million men will be suffering from erectile dysfunction by the year 2025 [2] . Erectile dysfunction and hypertension, a major factor for cardiovascular disease (CVD), are common conditions that possibly share pathophysiologic pathways. Compared with the general population, hypertensive patients have a higher prevalence of erectile dysfunction [3, 4] . However, an important point has been raised as to whether the higher prevalence of erectile dysfunction in those patients is the result of hypertension per se, of antihypertensive treatment, or as a combination of both. Studies in models of preclinical hypertension have suggested that high blood pressure (BP) causes morphological modifications in the penile vascular bed, contributing to erectile dysfunction. Furthermore, much evidence suggests that vascular abnormalities such as endothelial dysfunction and atherosclerosis play a critical role in both conditions [4, 5] . Importantly, the concept that erectile dysfunction is a prior indicator of CVD is growing stronger [6 & ].
Erectile dysfunction is often a disease of vascular origin. The penile endothelial bed is considered a specialized extension of the peripheral vascular system, responding similarly to various stimuli in order to maintain homeostasis, playing a particular regulatory role in the modulation of vascular smooth muscle (VSM) tone, which is crucial for normal erectile function [7 & ]. The small diameter of the cavernosal arteries and the high content of endothelium and VSM may make the penile vascular bed a sensitive indicator of systemic vascular disease [8] . Thus, the penis is a vascular organ that is sensitive to changes in oxidative stress and systemic nitric oxide levels. It is also sensitive to local modifications in the vasculature, making the penis an organ in which changes are supposed to precede vascular systemic alterations. Therefore, erectile dysfunction has a higher incidence in patients with hypertension, a disease that it often precedes. In addition, atherosclerotic disease associated with hypertension can interrupt normal erectile physiology, and it has been proposed that erectile dysfunction is not only significantly correlated with but is also strongly predictive of subsequent atherosclerosis [9 & ]. Atherosclerosis is characterized by the cross-talk between excessive inflammation and lipid accumulation. Development of atherosclerosis and vascular inflammation involves the Rho-kinase pathway, in which the main function is the regulation of VSM tone [10 & ]. Also, Rho-kinase signaling is dysregulated in hypertension, as well as, erectile dysfunction. Finally, both conditions are interconnected by many common agents, such as endothelin (ET-1), angiotensin II (AngII) and reactive oxygen species (ROS), and its pathways.
MECHANISMS OF ERECTION
Erectile dysfunction is defined as the regular inability to reach or maintain a penile erection of sufficient quality to perform satisfactory sexual intercourse; it has been progressively associated with many comorbidities. There are two main intracellular mechanisms for relaxing the cavernosal VSM leading to normal erectile function: the guanylate cyclase/cyclic guanosine monophosphate (cGMP) and adenylate cyclase/cyclic adenosine monophosphate (cAMP) pathways. Both pathways result in nitric oxide release, which is the main factor initiating erection. Nitric oxide is produced by endothelial (eNOS) or neuronal nitric oxide synthase (nNOS) via acetylcholine or neuronal stimulation. Upon its release, nitric oxide diffuses locally into adjacent VSM cells of the corpus cavernosum and binds to guanylate cyclase, which catalyzes the conversion of guanosine trisphosphate (GTP) to cGMP. Consequently, protein kinase G (PKG) is activated, leading to a decrease in cytosolic Ca 2þ by various mechanisms. cGMP also blocks Rho-kinase activation. The decay in cytosolic Ca 2þ concentration induces relaxation of the VSM cells in the penis, leading to dilation of arterial vessels and increased blood flow into the corpora cavernosa, allowing penile erection. Contributing to penile relaxation and reduction of intracellular Ca 2þ , other substances activate the enzyme adenylate cyclase, leading to cAMP production, which in turn activates protein kinase A (PKA) [7 & ]. The erectile process is completely dependent on relaxation and intact endothelial function, which is also true for vascular homeostasis and normal BP maintenance. cGMP and cAMP levels are modulated by phosphodiesterase (PDE) enzymes, which cleave these signaling molecules to GMP and AMP, respectively. Phosphodisterase-5 (PDE-5) is a key enzyme in the nitric oxide/cGMP signal transduction pathway and functions to restrain VSM relaxation and thus the erectile process. Another mechanism involved in maintenance of the erectile process is the phosphatidylinositol 3-kinase (PI3-kinase) pathway that activates the serine/threonine protein kinase Akt (also known as PKB). PKB causes direct phosphorylation of eNOS, reducing the enzyme's Ca 2þ requirement and causing increased production of nitric oxide. It has been suggested that rapid, brief activation of nNOS initiates the erectile process, whereas PI3-kinase/Akt-dependent phosphorylation and activation of eNOS by augmented blood flow and endothelial shear stress lead to sustained nitric oxide production and maximal erection [7 & ].
ERECTILE DYSFUNCTION IN HYPERTENSION
In the vasculature, as well in the penile tissue, circulating neurotransmitters, hormones and endothelium-derived factors play a critical role in
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modulating the VSM tone. During hypertension, disturbance of these factors can lead to an increase in VSM tone, which favors contraction.
Vasoconstrictors in hypertension and erectile function
Although the vascular endothelium is generally capable of self-repairing after sustaining damage, increasing vasoconstrictors may still affect the dynamic of vascular tone impairing normal erection or BP. Thus, upregulation of systemic or local vasoconstrictors such as angiotensin II or endothelin 1 may contribute to hypertension, as well as erectile dysfunction.
Angiotensin II This predominant bioactive component of the renin-angiotensin system (RAS) plays a role in the maintenance of systemic BP through various mechanisms in the cardiovascular and renal systems. Angiotensin II (AngII) also plays an important role in penile erection. However, an increase in circulating levels of AngII can lead to an increased VSM contraction and sodium retention, which contributes to the pathogenesis of hypertension. Some studies have shown that excessive production of AngII is associated with erectile dysfunction. AngII levels were also shown to be increased in the cavernous blood of men with erectile dysfunction as compared with healthy individuals [11, 12] . AngII exerts its biologic effect via activation of either one of its receptors: AT 1 or AT 2 . Whereas the AT 2 receptor has been shown to modulate vasodilation [13] , AT 1 receptor activation is known to modulate vasoconstriction, and induce VSM cell proliferation, inflammation, activation of the sympathetic nervous system, and aldosterone secretion. This is in addition to its effects on salt and water retention. In the penis, AngII modulates the tone of human penile arteries and trabecular VSM [14,15 & ]. AT 1 receptor blockade was shown to improve erectile function [16] . Jin et al. [17] have shown that AngII infusion in rats caused erectile dysfunction through the activation of NADPH oxidase, resulting in increased ROS. ROS are known to be detrimental to the endothelium and smooth muscle due to the direct scavenging of available nitric oxide necessary for vasorelaxation. ROS can also stimulate the RhoA/Rho-kinase pathway [11] . Stimulation of the RhoA/Rho-kinase pathway results in phosphorylation of the myosinbinding subunit of myosin light chain (MLC) phosphatase and inhibits its activity, thus promoting the phosphorylated state of MLC that leads to contraction and penile flaccidity.
Endothelin 1
Endothelin 1 (ET-1) is an endothelium-derived peptide and one of the most potent endogenous vasoconstrictors. ET-1 cellular signaling in the vasculature is similar to that of AngII. In mammalian cells, ET-1 exerts its biologic effect through the activation of its receptors: ET-A and ET-B. The typical receptor found in the smooth muscle cells is ET-A receptor, which mediates a vasoconstrictor effect. Penile VSM cells are able to synthesize ET-1, as well as respond to stimulation with ET-1 [18] . In addition, both ET-A and ET-B have been reported to be expressed in cavernosal tissue [19] [20] [21] [22] . In the penis, ET-1 induces corpus cavernosum vasoconstriction through the ET A receptor and subsequent activation of the inositol triphosphate (IP 3 )/Ca 2þ signaling pathway (Ca 2þ sensitive) and the RhoA/Rho-kinase signaling pathway (Ca 2þ independent) [23] . On the contrary, ET B receptor activation was shown to induce vasodilation by means of nitric oxide release from the cavernosal endothelial cells [24] .
In some forms of hypertension, ET-1 has been demonstrated to contribute to its pathogenesis, that is mineralocorticoid hypertension. It was shown that salt-sensitive hypertensive animals display abnormal vascular responses to ET-1, as well as increased tissue ET-1 expression. As mentioned previously, ROS are produced during hypertension; these ROS have been shown to also stimulate ET-1 production by endothelial cells, producing a cycle leading to further increases in vasoconstriction. Concurrently, ET-1 was shown to increase ROS generation via NADPH oxidase activation. Data from our laboratory have shown that ET-1 mediates not only penile vasoconstriction but also contraction of the internal pudendal artery, the major artery providing blood flow to the penis [22, 25] . We have also revealed that the corpus cavernosum from deoxycorticosterone acetate-salt hypertensive rats exhibits increased contractile responses to ET-1 when compared with their normotensive counterpart controls [22] .
Morphological changes in hypertension and erectile dysfunction
As blood vessels undergo remodeling during hypertension, the penile tissue also undergoes morphological changes [26, 27] . During hypertension, increases in wall thickness and collagen deposition, with a decrease in lumen diameter are common structural changes that can affect the vasculature. Studies have shown that hypertension was associated with erectile dysfunction, which may have resulted from a decrease in elastic fibers, increase of collagen fibers in the sinusoid, and a thinning of the tunica albuginea in the penis of hypertensive animals. Hypertension was associated also with endothelial and VSM cell damage and degenerated Schwann cells [26] . Also shown is an association of hypertension with increased VSM and cavernous VSM proliferation and fibrosis; moreover, hypertensive animals exhibited an increase in surrounding connective tissue in the amyelinated nerves, suggesting that the increase in extracellular matrix seems to affect not only the interstitium but also the neural structure of the penis resulting in erectile dysfunction [28] . In addition, the vascular changes in hypertension may affect the penile vasculature, as well as the pudendal arteries resulting in a decrease in blood supply to the penis [29] .
Vasodilators in hypertension and erectile dysfunction
Erectile dysfunction can result from either an increase in the production of or an abnormal response to contractile stimuli such as AngII and ET-1, or from a decrease in production or response to stimuli that favor penile VSM relaxation. These are similar hallmarks of endothelial dysfunction, which is defined as a decreased responsiveness to vasodilatory mediators and an increased sensitivity to vasoconstrictor molecules. These abnormal responses to mediators can affect the normal regulatory role of peripheral vascular endothelium, including the cavernosal arterial and venous systems.
Nitric oxide
During hypertension, there is a decrease in nitric oxide bioavailability, which may be due to decreased eNOS expression or uncoupling, as well as a decrease or impairment of the nitric oxide signaling pathway [30] . The decrease in nitric oxide bioavailability can result from nitric oxide scavenging by ROS, which is increased as result of NADPH activation and an alteration of intracellular antioxidant enzymes, including superoxide dismutase (SOD) [5, 17, 31] . Other studies using hypertensive animal models also showed an impairment of relaxation mediated by neurogenic nitric oxide [32] .
During hypertension, there is an imbalance between pro-oxidant and anti-oxidant mechanisms in the endothelial cells resulting in an increase in ROS generation. ROS are known to be very important in the pathophysiology of vascular disease. An interaction between ROS and nitric oxide has been implicated in many vascular diseases, such as atherogenesis, and has been suggested to play an important role in erectile dysfunction [33] . One of the most detrimental ROS is superoxide (O 2 À. ), which interacts with nitric oxide decreasing nitric oxide bioavailability and resulting in the formation of peroxynitrite (ONOO À ). In turn ONOO À was shown to cause damage to the mitochondria, which may contribute to apoptotic and necrotic cell death [34] . Although ONOO À was shown to mediate relaxation of rabbit corpus cavernosum, the relaxation to nitric oxide was short-lived with the contractile tension returning to its original level, whereas relaxation to ONOO À was less potent, of a slower onset and more prolonged with tissues unable to recover tension [35] . These will result in an ineffective relaxation in cavernosal tissue and may contribute to the pathogenesis of erectile dysfunction.
Hydrogen sulfide
Hydrogen sulfide (H 2 S) deficiency contributes to hypertension. H 2 S is produced from L-cysteine through cystathionine b-synthase (CBS) and cystathionine g-lyase (CSE). CBS is mainly expressed in the brain, peripheral nervous system, liver and kidney, whereas CSE is mostly found in liver, vascular and nonvascular smooth cells. Pharmacological inhibition or genetic deletion of the gene responsible for H 2 S synthesis, CSE, resulted in hypertension and a decrease in endothelium-mediated relaxation [36] . Recent studies have also shown that H 2 S can facilitate erectile function [37] . Interestingly, a recent study revealed that human penile tissue possesses both CBS and CSE. Both enzymes were found to be localized in the muscular trabeculae and the smooth muscle component of the penile artery. They also showed that human corpus cavernosum relaxes to exogenous H 2 S as well as L-cysteine in a dose-dependent manner [38] . Pharmacological inhibition of the H 2 S-producing enzymes was shown to decrease intracavernosal pressure in nonhuman primates, as well as increase electric field stimulation-mediated contraction in human corpus cavernosum [38, 39] 
ANTIHYPERTENSIVE PHARMACOLOGY
Despite the availability of more than 75 antihypertensive agents, BP control in the general population is, at best, inadequate, making hypertension a public health problem with estimated direct and indirect costs of more than US$ 93.5 billion per year [42] . In addition, combination pharmacotherapy is often required in order to reach the currently recommended BP goals in the majority of hypertensive patients. Drugs used to treat hypertension are classified as: diuretics, sympathoplegic agents, direct vasodilators, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARB). Erectile dysfunction is considered a common side effect of various antihypertensives, such as central-acting, b-blockers and diuretics [43] . However, newer-generation antihypertensive drugs, for example calcium antagonists and ACE inhibitors, seem to have neutral effects [44] . The first line of drugs for hypertension is b-blockers and diuretics. b-Blockers are a complex class of drugs involving several compounds that differ from each other by pharmacological characteristics, such as b1/b2 selectivity, intrinsic sympathomimetic activity and vasodilatory capacity. In general, they lower BP by reducing cardiac output, inhibiting renin release, AngII and aldosterone production, and decreasing adrenergic outflow from the central nervous system (CNS) [45 & ]. b-Blockers are indicated as a treatment for hypertensive patients with some specific organ damage, but they have been outlined as one of the leading causes of drug-related erectile dysfunction [46] . Diuretics act by depleting body sodium stores, which in the beginning causes a reduction in total blood volume, and consequently cardiac output. In turn, this initially causes an increase in peripheral vascular resistance, which is normalized after 6-8 weeks.
Direct vasodilators act by relaxing smooth muscle of arterioles and sometimes veins, reducing systemic vascular resistance. Some of them, such as hydralazine and minoxidil, have rarely been reported to cause erectile dysfunction. Calcium channels blockers, which dilate arteries by reducing calcium influx into cells, effectively lower BP. The currently available ones inhibit L-type channels in humans and seem to have a neutral effect on erectile function [47] . Possibly this is because this channel is linked with nNOS activation from cholinergic nerve endings into the penis, which is important for nitric oxide release and consequently erection. However, although this channel is inhibited, nNOS from nitrergic nerves will be activated, allowing the erectile process to begin. Another class of antihypertensive drugs is the ACE inhibitors. They act by mimicking the structure of the ACE substrate, directly blocking AngII formation and at the same time increasing bradykinin levels. The net results are reduced vasoconstriction, decreased sodium and water retention, and increased vasodilation through bradykinin.
As a future antihypertensive treatment, there is theoretical evidence that gene therapy may produce long-lasting antihypertensive effects by influencing the genes associated with hypertension. Nevertheless, the treatment of human essential hypertension requires sustained overexpression of genes and identification of target genes can be a challenging task, which is necessary for successful results. Also, many other problems are encountered in reaching a promising gene therapy. Among them is low efficiency for gene transfer into vascular cells, difficulties in determining how to prolong and control transgene expression or antisense inhibition, lack of selectivity and minimization of adverse effects of viral vectors. Despite these concerns, animal studies showed that gene therapy may be feasible to treat human hypertension. Another possibility is the utilization of vaccines as a treatment, albeit not in the near future [48] .
TREATMENT OF ERECTILE DYSFUNCTION IN HYPERTENSIVE PATIENTS
Although erectile dysfunction is often a result of hypertension, some studies have suggested that erectile dysfunction can also result from hypertension treatment. Whereas some studies did not find a significant influence, other suggested that antihypertension drugs, in particular diuretics and b-blockers, are associated with erectile dysfunction.
Given that AngII plays an important role in the cause of erectile dysfunction during hypertension, the use of ARB and ACE inhibitors was studied for their effects on erectile function. Animal studies showed that treatment with ARBs improves endothelial function in the cavernosal tissue. In humans, ARBs were shown to increase cavernosal relaxation mediated by non-adrenergic, non-cholinergic stimulation and sodium nitroprusside [15 & ]. Other studies have shown that treatment of hypertensive patients with ARBs resulted in improved sexual activity and erectile function. Whereas the use of ACE inhibitors in hypertensive animals showed improvement of erectile function, studies conducted in humans showed neutral to negative effects on sexual activity [44] .
As it was shown that ET-1 is a potent vasoconstrictor of corporal smooth muscle cells, some studies have focused on ET-A antagonism and its effect on erectile function. Current studies did show a significant alteration of the erectile response despite inhibition of contraction to exogenous ET-1 using ET-1 receptor antagonists. ET-1 plays an important role in mineralocorticoid hypertension and is directly involved in end-organ damage, so ET-1 receptor blockade may provide a therapeutic approach to this hypertensive condition, or other clinical conditions in which ET-1 levels are increased such as in diabetes and systemic sclerosis [49 & ].
The phosphodiesterase type 5 inhibitors (PDE5I) are approved treatment for erectile dysfunction. PDE5I act by inhibiting PDE5, the enzyme that catalyzes the breakdown of the second messenger cGMP. cGMP is the downstream effector in the nitric oxide signaling pathway, so, PDE5I are dependent upon the integrity of the nitric oxide generating system. In patients in whom the nitric oxide pathway is compromised, the benefits of such drugs will be lower when compared with others. The PDE5I are used also for the treatment of pulmonary hypertension (PAH). However, patients treated with nitrates or nitrate donors or vasodilators such as a-blockers should not take PDE5I, otherwise, combining these drugs will result in hypotension [50] .
Treatment with b-blockers is considered to cause erectile dysfunction. In fact, studies have shown that treatment of hypertensive patients with b-blockers is associated with sexual dysfunction and impotence. However, the new generation b-blocker nebivolol may have positive effects on erectile function. Recent studies showed that nebivolol treatment improves endothelial function and reverses erectile dysfunction in animals through the activation of the nitric oxide/cGMP pathway ]. In humans, nebivolol was shown to dilate penile arteries and treatment of hypertensive patients with nebivolol significantly improved erectile function [44] . More studies of the new generation of b-blockers are necessary to elucidate their effects on erectile function. Another treatment that was shown to be associated with erectile dysfunction is diuretic therapy. Treatment of patients with diuretics alone or with diuretics added to their therapy was shown to worsen sexual dysfunction [44] .
CONCLUSION
A common denominator in hypertension-associated erectile dysfunction is endothelial dysfunction. Even though erectile dysfunction and hypertension are both vascular diseases, various aspects regarding the disruption and modifications in the pathways (Fig. 1) leading to hypertension and erectile dysfunction remain to be elucidated. However, it is undeniable that many of the factors leading to hypertension also have contributed significantly to the erectile dysfunction process, and the opposite is also true. Also, erectile dysfunction can be a condition prior to hypertension or antihypertensive drug associated. It is expected that pathophysiological modifications resulting in erectile dysfunction can be more useful in the future to predict systemic vascular disorders such as hypertension.
